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Abstract
Background: Men with erectile dysfunction often have concurrent medical conditions. Conversely, men with these
conditions may also have underlying erectile dysfunction. The prevalence of unrecognized erectile dysfunction in
men with comorbidities commonly associated with erectile dysfunction was determined in men invited to
participate in a double-blind, randomized, placebo-controlled trial of sildenafil citrate.
Methods: Men ≥30 years old presenting with ≥1 erectile dysfunction risk factor (controlled hypertension,
hypercholesterolemia, smoking, metabolic syndrome, stable coronary artery disease, diabetes, depression, lower
urinary tract symptoms, obesity [body mass index ≥30 kg/m
2] or waist circumference ≥40 inches), and not
previously diagnosed with erectile dysfunction were evaluated. The screening question, “Do you have erectile
dysfunction?,” with responses of “no,”“ yes,” and “unsure,” and the Erectile Function domain of the International
Index of Erectile Function (IIEF-EF) were administered.
Results: Of 1084 men screened, 1053 answered the screening question and also had IIEF-EF scores. IIEF-EF scores
indicating erectile dysfunction occurred in 71% (744/1053), of whom 54% (399/744) had moderate or severe
erectile dysfunction. Of 139 answering “yes,” 526 answering “unsure,” and 388 answering “no,” 96%, 90%, and 36%,
respectively, had some degree of erectile dysfunction. The mean±SD (range) number of risk factors was 2.9 ± 1.7
(3-8) in the “yes” group, 3.2 ± 1.7 (3-9) in the “unsure” group, and 2.6 ± 1.5 (2-8) in the “no” group.
Conclusion: Although awareness of having erectile dysfunction was low, most men with risk factors had IIEF-EF
scores indicating erectile dysfunction. Erectile dysfunction should be suspected and assessed in men with risk
factors, regardless of their apparent level of awareness of erectile dysfunction.
Trial registration: ClinicalTrials.gov Identifier NCT00343200.
Background
Erectile dysfunction affects quality of life and may be
associated with depression [1-4]. Men with erectile dys-
function often have other comorbidities such as dia-
betes, hypertension, and coronary artery disease [5-8].
Conversely, men consulting with their physician for
comorbidities or other risk factors for erectile dysfunc-
tion may also have underlying erectile dysfunction,
which may or may not be recognized.
Erectile dysfunction is defined as the inability to attain
or maintain an erection sufficient for satisfactory sexual
performance [9]. However, men who experience a
change in their ability to achieve an erection might not
immediately recognize that erectile dysfunction is the
problem. The quality of men’s erections deteriorates
gradually over time. Consequently, men may be uncer-
tain whether their erectile difficulties are permanent or
temporary [10] and may wait to see if the erectile dys-
function resolves on its own [11]. Alternatively, the
stigma or embarrassment of having erectile dysfunction
symptoms may lead to denial of the problem [10,11].
We hypothesized that men with comorbidities and
risk factors associated with erectile dysfunction fre-
quently have this condition but might deny it and not
identify themselves as erectile dysfunction sufferers.
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a screening strategy for men with erectile dysfunction-
associated comorbidities and risk factors who do not
self-identify as having erectile dysfunction. The objective
was to create a profile of these men by describing the
general characteristics (demographics, comorbidities,
and risk factors) of men who answered the question,
“Do you have erectile dysfunction?” with “yes,”“ no,” or
“unsure” responses. Such information is needed in order
to allow formulation of strategies to identify previously
unrecognized or undiagnosed erectile dysfunction in
order that it may be addressed as a medical condition.
Methods
Men were recruited for a men’s health study without
mention of erectile dysfunction. At the screening visit
for this sildenafil flexible-dose, double-blind, placebo-
controlled trial, [12] written informed consent was
obtained, and demographic data and the patient’s history
of risk factor(s) were collected. The protocol was
approved by the Institutional Review Board of each par-
ticipating center, and the study was conducted in com-
pliance with the ethical principles originating in or
derived from the Declaration of Helsinki and in compli-
ance with all International Conference on Harmoniza-
tion Good Clinical Practice Guidelines. Men ≥30 years
of age who presented with at least 1 risk factor or
comorbidity for erectile dysfunction (controlled hyper-
tension, hypercholesterolemi a ,s m o k i n g ,m e t a b o l i cs y n -
drome, stable coronary artery disease, diabetes,
depression, lower urinary tract symptoms [LUTS], obe-
sity [defined as body mass index [BMI] ≥30 kg/m
2]o r
waist circumference ≥40 inches) and who had not been
previously diagnosed with erectile dysfunction were eli-
gible for screening.
Key exclusion criteria included hypotension, current
or anticipated nitrate or nitric oxide donor treatment,
significant cardiovascular disease within the past 3
months, and previous use of more than 6 doses of any
phosphodiesterase type 5 inhibitor.
Men were asked the screening question, “Do you have
erectile dysfunction?” a n da d m i n i s t e r e dt h eE r e c t i l e
Function domain of the International Index of Erectile
Function (IIEF-EF) [13]. Those who answered “no” or
“unsure” to the erectile dysfunction question and who
had any degree of erectile dysfunction (scored ≤25 out
of 30 on the IIEF-EF) [14] were eligible for inclusion
into the double-blind, placebo-controlled trial [12]. The
results of the screening analysis are reported here.
Results
Of the 1084 men screened, 1079 responded to the erec-
tile dysfunction screening question and 1053 also had
IIEF-EF scores (Figure 1). Overall, IIEF-EF indicative of
erectile dysfunction were noted in 71% (744/1053) of
men, of whom 54% (399/744) had moderate or severe
erectile dysfunction (IIEF-EF score ≤16), 23% (171/744)
had mild-to-moderate erectile dysfunction (IIEF-EF
score 17-21), and 23% (174/744) had mild erectile dys-
function (IIEF-EF score 22-25).
One hundred thirty-nine men responded “yes” to the
erectile dysfunction screening question and also com-
pleted the IIEF-EF; of these, 96% had IIEF-EF scores
consistent with some degree of erectile dysfunction. Of
those who answered “no” to the screening question
(388/1053), 36% had also had IIEF-EF scores which indi-
cated some degree of erectile dysfunction. Of those who
answered “unsure” to the screening question (526/1053),
90% had IIEF-EF scores which indicated some degree of
erectile dysfunction.
Although the mean age of the groups with “no” or
“unsure” responses was 50 and 52 years, respectively,
there were more men 45 years or older in the “unsure”
g r o u p( 7 5 % )( T a b l e1 ) .T h e“yes” group had the highest
mean age (59 years), and the greatest percentage of
those aged 65 years or older (32%).
A correct erectile dysfunction diagnosis was more
common for men who answered the screening question,
“Do you have erectile dysfunction?” with the response of
“yes” or “no” (Figure 2). Men who answered “yes”
tended to have more severe erectile dysfunction, with
49% having severe erectile dysfunction (IIEF-EF score
≤10) and only 4% having no erectile dysfunction (IIEF-
EF score ≥26). Men who answered “no” tended to have
no or less severe erectile dysfunction, with only 6% hav-
ing severe erectile dysfunction and 64% having no erec-
tile dysfunction. The severity of erectile dysfunction in
men who were unsure was almost equally distributed
among the categories.
The mean number of erectile dysfunction risk factors
was similar for all 3 erectile dysfunction screening
response groups, with the mean ± SD of 2.9 ± 1.7
(range, 3-8) in the “yes” group, 2.6 ± 1.5 (range, 2-8) in
the “no” group, and 3.2 ± 1.7 (range, 3-9) in the
“unsure” group. Within each response group, hyperten-
sion, hypercholesterolemia, BMI ≥30 kg/m
2,a n dw a i s t
circumference ≥40 inches occurred most frequently. For
each risk factor, an “unsure” response was most com-
mon (48%-62%; vs “no,” 23%-39%; vs “yes,” 9%-27%)
(Table 2).
The erectile dysfunction severity profiles for each
response group for the individual comorbidities gener-
ally reflected the pattern observed in the overall popula-
tion; most men who answered “no” to the screening
question had no erectile dysfunction or mild erectile
dysfunction, those who answered “yes” had mostly mod-
erate and severe erectile dysfunction, and those who
answered “unsure” had erectile dysfunction severity that
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function severity categories (Figure 3). However, in the
subgroups of men with coronary artery disease and
those with diabetes, a higher proportion of men in the
“unsure” groups had severe erectile dysfunction com-
pared with the other comorbidities.
Discussion
Our screening for erectile dysfunction among men with
an erectile dysfunction-associated comorbidity and risk
factors showed a high prevalence of erectile dysfunction
diagnosed with the IIEF-EF (71%), with more than half
of these (54%) having moderate or severe dysfunction,
Figure 1 Erectile dysfunction severity by screening question response. IIEF-EF = Erectile Function domain of the International Index of
Erectile Function. Using the IIEF-EF, erectile dysfunction severity categories are no ED (score ≥26 out of 30) mild (score 22-25), mild-to-moderate
(score 17-21), moderate (score 11-16), and severe (score ≤10)[13,14].
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ing mild dysfunction. This supports recently reported
results showing that even mild erectile dysfunction is an
important indicator of risk for underlying disease asso-
ciated with erectile dysfunction, results from the first
prospective, randomized, double-blind trial to assess
treatment with a phosphodiesterase type 5 inhibitor in a
population of sexually dissatisfied men selected for mild
ED diagnosed with the IIEF-EF [15]. That landmark trial
also showed that sildenafil treatment was efficacious and
well tolerated and the men were highly satisfied with
their treatment [16]–thus validating both early interven-
tion and the IIEF-EF diagnostic classification of mild
erectile dysfunction in men who (per the inclusion cri-
teria) have normal gonadal function, have regular sexual
activity, and are sexually dissatisfied. Sexual dissatisfac-
tion or “bother”, which can be assessed using the Erec-
tion Distress Scale [17] or the Overall Satisfaction
domain of the IIEF, may be an important part of the
equation in a man’s self-perception of erectile dysfunc-
tion, regardless of the severity of the dysfunction.
Table 1 Patient Characteristics by Response to the Screening Question, “Do You Have Erectile Dysfunction?”
Yes
(n = 139)
No
(n = 388)
Unsure
(n = 526)
Total
(N = 1053)
†
Mean age, y (range) 59 (36-82) 50 (29-78) 52 (29-85) 52 (29-85)
Age distribution, n (%)
18-44 y 9 (6) 127 (33) 129 (25) 265 (25)
45-64 y 86 (62) 222 (57) 343 (65) 651 (62)
≥65 y 44 (32) 39 (10) 54 (10) 137 (13)
Race, n (%)
White 113 (81) 317 (82) 380 (72) 810 (77)
Black 12 (9) 48 (12) 95 (18) 155 (15)
Asian 3 (2) 3 (1) 3 (1) 9 (1)
Other 9 (6) 20 (5) 48 (9) 77 (7)
Missing 2 (1) 0 0 2 (< 1)
Mean weight, kg (range)* 92.0 (64.4-143.3) 95.9 (57.6-155.6) 99.7 (56.7-195) 97.4 (56.7-195)
Mean height, cm (range)* 177 (160-193) 178 (152-193) 178 (150-198) 178 (150-198)
*Data available for 971 subjects.
†Patients with both erectile dysfunction screening question and Erectile Function domain of the International Index of Erectile Function data.
Figure 2 Erectile dysfunction severity at screening. Erectile
dysfunction severity at screening was based on Erectile Function
Domain of the International Index of Erectile Function score in men
who responded “yes,”“ no,” or “unsure” to the question, “Do you
have erectile dysfunction?” Percentages with each erectile
dysfunction severity category were calculated within the individual
response groups ("yes,”“ no,” or “unsure”). Erectile Function domain
of the International Index of Erectile Function severity categories are
no ED (score ≥26 out of 30), mild (score 22-25), mild-to-moderate
(score 17-21), moderate (score 11-16), and severe (score ≤10)[13,14].
Table 2 Erectile Dysfunction Screening Response Within
Each Risk Factor Group*
Yes, % No, % Unsure, %
Risk Factor n (n = 139) (n = 388) (n = 526)
Hypertension 552 15 33 52
Hypercholesterolemia 545 13 39 48
Obesity
† 477 9 36 55
Smoking 400 9 32 60
Waist ≥40 inches 374 11 32 58
Diabetes 234 23 26 52
Depression 227 9 29 62
LUTS 119 19 26 56
Coronary artery disease 62 27 23 50
Metabolic syndrome 43 16 30 54
BMI = body mass index; LUTS = lower urinary tract symptoms.
*Patients with both erectile dysfunction screening question and Erectile
Function domain of the International Index of Erectile Function data.
†BMI ≥30 kg/m
2.
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function severity differed by answer to the erectile dys-
function screening question, with a majority of men
who answered “yes” having mostly moderate to severe
erectile dysfunction. Likewise, men who answered “no”
to the screening question had mostly no or mild erectile
dysfunction (IIEF-EF score ≥22), although 6% of men
who answered “no” had severe dysfunction according to
the IIEF-EF assessment (IIEF-EF score ≤10). Men who
were unsure whether they had erectile dysfunction most
often did have some degree of erectile dysfunction, but
the severity was variable.
Interestingly, a higher percentage of men in the
“unsure” and overall groups with coronary artery disease
or diabetes had severe erectile dysfunction compared
with the other erectile dysfunction severity categories.
The results for coronary artery disease are similar to
those from a previous study showing 14% mild, 21%
mild-to-moderate, 14% moderate, and 51% severe erec-
tile dysfunction in men admitted to the emergency
room with acute coronary syndrome and subsequently
diagnosed with coronary artery disease [8]. Likewise, a
s t u d yi nd i a b e t i cm e nw i t he r ectile dysfunction showed
that these men had significantly lower scores on the
IIEF-EF than men without diabetes, with a mean IIEF-
EF score of 6 (severe erectile dysfunction) [18].
A limitation of the trial design was that the reasons
for men’s specific answers to the screening question
were not further investigated. However, studies investi-
gating treatment-seeking behavior of men with erectile
dysfunction and those assessing men’ss e x u a la t t i t u d e s
and beliefs may serve to provide insight into how men
react when they begin to experience erectile dysfunction
as well as why some men may not recognize that they
have erectile dysfunction.
Erectile dysfunction may produce a profound sense of
loss [10]. Men may try to make sense of the cause of
their erectile dysfunction, which may include guilt or
the pressures of business or work, or they may want to
confirm that an existing medical problem is the cause
rather than their feelings for their partner or their sexu-
ality. Men frequently cited psychological stress, organic
disease, and aging as causes for erectile dysfunction in a
study of men’s sexual beliefs and attitudes [19]. Men’s
emotional reactions to erectile dysfunction include
denial, embarrassment, depression, and acceptance [10].
Figure 3 Comparison of erectile dysfunction severity in comorbidity subgroups by screening question response. LUTS = lower urinary
tract symptoms. Erectile Function domain of the International Index of Erectile Function severity categories are no ED (score ≥26 out of 30),
mild (score 22-25), mild-to-moderate (score 17-21), moderate (score 11-16), and severe (score ≤10)[13,14].
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tion problems are less likely to seek treatment [20]. The
duration and severity of erectile dysfunction was also
determined to be a factor in whether men sought treat-
ment, [11,20,21] suggesting that erectile dysfunction
symptoms may not be immediately recognized. When
considered together, these factors suggest that for men
who answered “no” or “unsure” in the current study and
were identified as having erectile dysfunction by IIEF-EF
score, the onset of erectile dysfunction symptoms may
have been poorly understood, not recognized as erectile
dysfunction, or may have been denied.
Men who answered “yes” to the screening question
and had erectile dysfunction apparently recognized that
they had this condition, but had not been previously
diagnosed. This suggests that these men may not have
been interested in or were reluctant to seek resolution
or treatment for their erectile dysfunction. Some treat-
ment-seeking barriers that may explain why men with
recognized erectile dysfunction do not seek treatment
for it include the belief that erectile dysfunction is a nat-
ural part of aging, [19,20] concern about the side effects
of or not wanting to take drugs, [19,20] the belief that
nothing can be done about erectile dysfunction, [20]
fear that the underlying condition causing erectile dys-
function may be serious, [20] and the cost of treatment
[19,20]. One study found that men would prefer to pur-
chase erectile dysfunction medications anonymously or
wanted the medication to be available without a pre-
scription, [19] suggesting that men may feel embar-
rassed about purchasing erectile dysfunction
medications.
All men who were screened had comorbidities asso-
ciated with erectile dysfunction. Pharmaceutical treat-
ments for many of these erectile dysfunction-associated
disorders are associated with sexual side effects, includ-
ing erectile dysfunction. For example, fibrate derivatives
used to treat hypercholesterolemia [22] and diuretics
and b-blockers for treatment of hypertension have been
associated with erectile dysfunction [23]. Drugs for
LUTS [24] and depression [25] can also impact sexual
health. Men who first experience erectile dysfunction
after beginning medication to treat a comorbidity may
n o tc o n s i d e rt h a tt h e yh a v ee r e c t i l ed y s f u n c t i o n ,b u t
may feel that their erectile dysfunction is an adverse
effect of their treatment.
Conclusions
This study found that many men with risk factors asso-
ciated with erectile dysfunction did have erectile dys-
function, including 54% who had moderate or severe
dysfunction; however, these men’sa w a r e n e s so fh a v i n g
erectile dysfunction was low. The results suggest that
many men may not recognize that they have erectile
dysfunction, may possibly deny it, or may not view erec-
tile dysfunction symptoms as a medical problem. Con-
sidering the impact that erectile dysfunction has on
quality of life and that it may often respond to treat-
ment, erectile dysfunction should be suspected and
assessed in men with risk factors, such as cardiovascular
disease, diabetes, and LUTS, regardless of their apparent
level of awareness of erectile dysfunction.
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